The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.
Although the cure rate of lymphoma has been increased due to the development of newer effective drugs, a substantial portion of patients is still suffered from relapse. Furthermore, the treatment-related morbidity is another factor which can make the treatment outcome worse in patients with lymphoma, especially elderly patients. Thus, this study is going to assess following factors which amy probably affect the treatment outcome and the risk of treatment-related morbidity. 1. Biologic factors associated with the aggressiveness of lymphoma * molecular markers in serum, cytogenetic markers 2. Factors associated with the risk of treatment-related morbidity * comorbidity, nutrition status, performance status, quality of life at diagnosis
Study Type
INTERVENTIONAL
Allocation
NA
Masking
NONE
Enrollment
953
Treatment regimen will be determined by the sub-type of lymphoma
Samsung Medical Center
Seoul, South Korea
all cause mortality
Time frame: 5 years
Treatment response
Time frame: after completion of primary therapy
Rate of occurrence of toxicity
Time frame: 2 years from the start of the 1st therapy
Treatment-related morbidity
Time frame: within 60 days from the previous therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.